In contrast with preclinical data suggesting that activation of the β-catenin pathway in melanoma cells associates with resistance to anti-PD-L1/anti-CTLA-4 antibody therapy [11], we found that more than 50% of patients with APC/CTNNB1 genetic aberrations responded to immunotherapies. This evidence concerns the gene CTNNB1 and melanoma.